Noxopharm to Prioritise Cutting-Edge ChromaTM & SofraTM Programs
Posted: 6 April 2023 Innovative biotech company Noxopharm Limited (ASX:NOX) announces that as part of the Board and management team’s continual operational risk and cost profile evaluation, the company has reviewed the opportunities for its growing portfolio of…
4DMedical signs first US hospital SaaS contract
Posted: 6 April 2023 Respiratory imaging technology company 4DMedical Limited today announces a significant milestone in its commercialisation journey with the signing of a five-year contract with the University of Miami to provide XV LVAS® (X-ray Velocimetry Lung…
Brain cancer trial platform to transform research and treatment
Posted: 4 April 2023 A world-first clinical trial platform is set to transform research into new therapies for brain cancer, delivering more targeted, personalised treatment for patients. The Brain-POP (brain perioperative) clinical trial platform enables doctors to precisely…
Nasodine COVID-19 Trial Concludes Recruitment – Results in June 2023
Posted: 4 April 2023 Firebrick Pharma is pleased to announce that its Phase 2 COVID-19 trial of Nasodine Nasal Spray has closed for recruitment. Nasal swabs collected from all subjects have been forwarded to a specialist virology laboratory…
Avecho Biotechnology Conducts Entiltlement Offer to Raise $11M to Fund Pivotal Phase III Clinical Trial
Posted: 4 April 2023 Avecho Biotechnology Limited has today announced that it is undertaking a capital raise seeking approximately $11 million. Proceeds from the raise will be used to fund a pivotal Phase 3 clinical trial designed to test…
Optiscan Establishes US Commercial Operation in Minnesota
Posted: 4 April 2023 Optiscan Imaging Limited is pleased to announce the establishment of a new commercial operation in the United States. The expansion includes the formalisation of Optiscan Imaging, Inc. as a standalone US legal entity, along…
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
Posted: 3 April 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive final data from Part B of the TACTI-002 Phase II trial in 2nd line…
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer
Posted: 3 April 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has signed an agreement to expand the INSIGHT-003…
Surgery game-changer
Posted: 31 March 2023 St Vincent’s Hospital Melbourne has become the first public hospital in Australia to install the Synaptive Modus V – a robotic exoscope powered by artificial intelligence voice control that provides surgical teams with 3D…
Networking the Monash research and innovation ecosystem
Posted: 31 March 2023 Last week, Mr Matt Fregon MP, Victorian Member for Ashwood, officially launched the Monash Precinct Network, which will further accelerate the growth of the City of Monash as an international destination of global research…
Atmo Biosciences closes fully subscribed $8 million Series B funding round
Posted: 31 March 2023 Atmo Biosciences, a company commercialising the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, has raised A$8 million in a fully subscribed Series B funding round. The raise…
Noxopharm Announces Novel mRNA Vaccine Enhancer
Posted: 29 March 2023 Innovative biotech company Noxopharm Limited (ASX:NOX) announces the development of a new proprietary product candidate based on mRNA technology as part of the company’s SofraTM preclinical platform. A lead candidate has now been selected…
